United States Biotechnology & Medical Research

Chimerix Inc (CMRX)

Track

Ticker: CMRX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Chimerix Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Melemed Allen S.
CHIEF MEDICAL OFFICER
1 sale — total 13,799 USD
Planned sale 13 Feb 2025
Value US$4,425,953.58 | Price 443.96 | Shares 39,687
Planned sale 13 Feb 2025
Value US$2,036,022.60 | Price 319.63 | Shares 85,326
Planned sale 13 Feb 2025
Value US$7,226.40 | Price 4.52 | Shares 1,600
Planned sale 13 Feb 2025
Value US$10,195.54 | Price 4.51 | Shares 2,260
Planned sale 13 Feb 2025
Value US$33,282.18 | Price 4.52 | Shares 7,370
Proposed sale 13 Feb 2025
Value US$14,700.00 | Price 4.20 | Shares 3,500
Proposed sale 13 Feb 2025
Value US$8,400.00 | Price 4.20 | Shares 2,000
Proposed sale 13 Feb 2025
Value US$33,600.00 | Price 4.20 | Shares 8,000
Proposed sale 13 Feb 2025
Value US$10,500.00 | Price 4.20 | Shares 2,500
Proposed sale 13 Feb 2025
Value US$2,100.00 | Price 4.20 | Shares 500
Planned sale 30 Jan 2025
Value US$11,470.20 | Price 4.10 | Shares 2,800
Planned sale 30 Jan 2025
Value US$4,171.65 | Price 4.11 | Shares 1,015
Planned sale 30 Jan 2025
Value US$9,636.18 | Price 4.10 | Shares 2,350
Proposed sale 30 Jan 2025
Value US$12,000.00 | Price 4.00 | Shares 3,000
Proposed sale 30 Jan 2025
Value US$4,400.00 | Price 4.00 | Shares 1,100
Proposed sale 30 Jan 2025
Value US$10,000.00 | Price 4.00 | Shares 2,500
Proposed sale 8 Aug 2024
Value US$1,300.00 | Price 0.87 | Shares 1,500
Planned sale 8 Aug 2024
Value US$1,064.62 | Price 0.83 | Shares 1,285
Planned sale 14 Feb 2024
Value US$2,776.77 | Price 1.04 | Shares 2,660
Planned sale 14 Feb 2024
Value US$1,809.40 | Price 1.04 | Shares 1,744
Planned sale 14 Feb 2024
Value US$2,022.64 | Price 1.04 | Shares 1,940
Proposed sale 14 Feb 2024
Value US$2,100.00 | Price 1.05 | Shares 2,000
Proposed sale 14 Feb 2024
Value US$2,625.00 | Price 1.05 | Shares 2,500
Proposed sale 14 Feb 2024
Value US$3,675.00 | Price 1.05 | Shares 3,500
Buy 17 Nov 2023
Value US$16,521.91 | Price 0.96 | Shares 17,295
Buy 10 Nov 2023
Value US$2,488.60 | Price 0.92 | Shares 2,705
Proposed sale 28 Sep 2023
Value US$4,000.00 | Price 1.00 | Shares 4,000
Planned sale 28 Sep 2023
Value US$3,583.65 | Price 0.99 | Shares 3,610
Buy 25 Sep 2023
Value US$19,636.00 | Price 0.98 | Shares 20,000
Planned buy 18 May 2023
Value US$59,149.97 | Price 1.14 | Shares 51,700
Buy 12 May 2023
Value US$84,121.82 | Price 1.12 | Shares 75,015
Buy 12 May 2023
Value US$13,529.87 | Price 1.13 | Shares 11,985
Buy 10 May 2023
Value US$19,980.00 | Price 1.11 | Shares 18,000
Buy 8 May 2023
Value US$9,975.00 | Price 1.14 | Shares 8,750
Buy 28 Mar 2023
Value US$24,152.00 | Price 1.21 | Shares 20,000
Planned sale 26 Jan 2023
Value US$5,686.42 | Price 1.76 | Shares 3,230
Buy 29 Sep 2022
Value US$37,176.00 | Price 1.86 | Shares 20,000
Buy 19 May 2022
Value US$2,908.95 | Price 2.05 | Shares 1,419
Buy 19 May 2022
Value US$20,560.86 | Price 2.06 | Shares 9,981
Buy 19 May 2022
Value US$40,738.00 | Price 2.04 | Shares 20,000
Planned buy 17 May 2022
Value US$25,635.00 | Price 1.71 | Shares 15,000
Buy 17 May 2022
Value US$16,100.00 | Price 1.61 | Shares 10,000
Planned sale 4 Feb 2022
Value US$18,355.26 | Price 5.56 | Shares 3,300
Buy 28 Jun 2021
Value US$54,418.50 | Price 7.83 | Shares 6,950
Buy 25 Jun 2021
Value US$23,729.00 | Price 7.78 | Shares 3,050
Planned sale 5 Apr 2021
Value US$12,427.32 | Price 9.68 | Shares 1,284
Buy 1 Mar 2021
Value US$14,700.00 | Price 9.80 | Shares 1,500
Planned sale 28 Jan 2021
Value US$27,649.92 | Price 8.61 | Shares 3,211
Planned sale 2 Oct 2020
Value US$10,589.60 | Price 2.48 | Shares 4,270
Buy 19 Aug 2020
Value US$10,220.00 | Price 2.92 | Shares 3,500
Planned sale 10 Aug 2020
Value US$5,148.48 | Price 3.25 | Shares 1,584
Planned sale 7 Aug 2020
Value US$8,125.00 | Price 3.25 | Shares 2,500
Planned sale 6 Aug 2020
Value US$8,223.75 | Price 3.29 | Shares 2,500
Planned sale 5 Aug 2020
Value US$8,187.25 | Price 3.27 | Shares 2,500
Planned sale 4 Aug 2020
Value US$16,250.00 | Price 3.25 | Shares 5,000
Planned buy 16 Mar 2020
Value US$47,522.43 | Price 1.43 | Shares 33,300
Buy 12 Mar 2020
Value US$105,652.96 | Price 1.45 | Shares 72,995
Buy 12 Mar 2020
Value US$69,900.00 | Price 1.40 | Shares 50,000
Sale 10 Feb 2020
Value US$14,830.26 | Price 1.68 | Shares 8,805
Sale 7 Feb 2020
Value US$4,335.00 | Price 1.70 | Shares 2,550
Sale 7 Feb 2020
Value US$3,893.00 | Price 1.70 | Shares 2,290
Sale 7 Jan 2020
Value US$66,044.84 | Price 2.15 | Shares 30,680
Buy 13 Nov 2019
Value US$54,567.00 | Price 1.82 | Shares 30,000
Buy 11 Nov 2019
Value US$33,190.00 | Price 1.66 | Shares 20,000
Buy 6 Nov 2019
Value US$156,000.00 | Price 1.56 | Shares 100,000
Buy 6 Nov 2019
Value US$15,797.00 | Price 1.58 | Shares 10,000
Buy 28 May 2019
Value US$64,800.00 | Price 3.60 | Shares 18,000
Buy 20 May 2019
Value US$104,316.00 | Price 3.48 | Shares 30,000
Buy 10 May 2019
Value US$87,678.00 | Price 2.92 | Shares 30,000
Buy 12 Jun 2018
Value US$45,015.00 | Price 4.50 | Shares 10,000
Sale 18 May 2018
Value US$72,142.50 | Price 4.81 | Shares 15,000
Sale 17 May 2018
Value US$143,931.00 | Price 4.80 | Shares 30,000
Sale 16 May 2018
Value US$143,808.00 | Price 4.79 | Shares 30,000
Sale 15 May 2018
Value US$140,808.00 | Price 4.69 | Shares 30,000
Sale 14 May 2018
Value US$105,232.30 | Price 4.67 | Shares 22,553
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-14 2025-02-13 PlS Planned sale
Melemed Allen S.

CHIEF MEDICAL OFFICER

Officer
39,687 -21.9%
443.96
US$4,425,954 		39,687 -21.9% 443.96 US$4,425,954
2025-02-14 2025-02-13 PlS Planned sale
1.3
Jakeman David

VP OF FINANCE AND ACCOUNTING

Officer
85,326 -4.4%
319.63
US$2,036,023 		85,326 -4.4% 319.63 US$2,036,023
2025-02-14 2025-02-13 PlS Planned sale
Alrutz Michael Albert

SVP AND GENERAL COUNSEL

Officer
80,210 +26.7%
374.23
US$3,783,088 		80,210 +26.7% 374.23 US$3,783,088
2025-02-14 2025-02-13 PlS Planned sale
LaSpaluto Michelle

CHIEF FINANCIAL OFFICER

Officer
2,260 -1.3%
4.51
US$10,196 		2,260 -1.3% 4.51 US$10,196
2025-02-14 2025-02-13 PlS Planned sale
3.1
Andriole Michael T.

PRESIDENT AND CEO

Executive Director
7,370 -1.2%
4.52
US$33,282 		7,370 -1.2% 4.52 US$33,282
2025-02-13 2025-02-13 PrS Proposed sale
Allen Melemed

Officer

Officer
3,500
4.20
US$14,700 		3,500 4.20 US$14,700
2025-02-13 2025-02-13 PrS Proposed sale
Michael Alrutz

Officer

Officer
2,000
4.20
US$8,400 		2,000 4.20 US$8,400
2025-02-13 2025-02-13 PrS Proposed sale
3.1
Michael Andriole

Officer

Officer
8,000
4.20
US$33,600 		8,000 4.20 US$33,600
2025-02-13 2025-02-13 PrS Proposed sale
Michelle LaSpaluto

Officer

Officer
2,500
4.20
US$10,500 		2,500 4.20 US$10,500
2025-02-13 2025-02-13 PrS Proposed sale
1.3
Dave Jakeman

Officer

Officer
500
4.20
US$2,100 		500 4.20 US$2,100
2025-01-31 2025-01-30 PlS Planned sale
1.3
Jakeman David

VP OF FINANCE AND ACCOUNTING

Officer
2,800 -1.8%
4.10
US$11,470 		2,800 -1.8% 4.10 US$11,470
2025-01-31 2025-01-30 PlS Planned sale
LaSpaluto Michelle

CHIEF FINANCIAL OFFICER

Officer
1,015 -0.6%
4.11
US$4,172 		1,015 -0.6% 4.11 US$4,172
2025-01-31 2025-01-30 PlS Planned sale
3.1
Andriole Michael T.

PRESIDENT AND CEO

Executive Director
2,350 -0.4%
4.10
US$9,636 		2,350 -0.4% 4.10 US$9,636
2025-01-30 2025-01-30 PrS Proposed sale
1.3
David Jakeman

Officer

Officer
3,000
4.00
US$12,000 		3,000 4.00 US$12,000
2025-01-30 2025-01-30 PrS Proposed sale
Michelle LaSpaluto

Officer

Officer
1,100
4.00
US$4,400 		1,100 4.00 US$4,400
2025-01-30 2025-01-30 PrS Proposed sale
3.1
Michael Andriole

Officer

Officer
2,500
4.00
US$10,000 		2,500 4.00 US$10,000
2024-08-09 2024-08-08 PrS Proposed sale
3.1
Michael Andriole

Officer

Officer
1,500
0.87
US$1,300 		1,500 0.87 US$1,300
2024-08-09 2024-08-08 PlS Planned sale
3.1
Andriole Michael T.

PRESIDENT AND CEO

Executive Director
1,285 -0.3%
0.83
US$1,065 		1,285 -0.3% 0.83 US$1,065
2024-02-16 2024-02-14 PlS Planned sale
1.3
Jakeman David

VP OF FINANCE AND ACCOUNTING

Officer
2,660 -1.8%
1.04
US$2,777 		2,660 -1.8% 1.04 US$2,777
2024-02-16 2024-02-14 PlS Planned sale
3.1
Andriole Michael T.

PRESIDENT AND CEO

Executive Director
1,744 -0.4%
1.04
US$1,809 		1,744 -0.4% 1.04 US$1,809
2024-02-16 2024-02-14 PlS Planned sale
LaSpaluto Michelle

CHIEF FINANCIAL OFFICER

Officer
1,940 -1.7%
1.04
US$2,023 		1,940 -1.7% 1.04 US$2,023
2024-02-14 2024-02-14 PrS Proposed sale
3.1
Michael Andriole

Officer

Officer
2,000
1.05
US$2,100 		2,000 1.05 US$2,100
2024-02-14 2024-02-14 PrS Proposed sale
Michelle Laspaluto

Officer

Officer
2,500
1.05
US$2,625 		2,500 1.05 US$2,625
2024-02-14 2024-02-14 PrS Proposed sale
1.3
David Jakeman

Officer

Officer
3,500
1.05
US$3,675 		3,500 1.05 US$3,675
2023-11-20 2023-11-17 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
17,295 +20.9%
0.96
US$16,522 		17,295 +20.9% 0.96 US$16,522
2023-11-13 2023-11-10 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
2,705 +3.4%
0.92
US$2,489 		2,705 +3.4% 0.92 US$2,489
2023-09-28 2023-09-28 PrS Proposed sale
1.3
David Jakeman

Officer

Officer
4,000
1.00
US$4,000 		4,000 1.00 US$4,000
2023-09-28 2023-09-28 PlS Planned sale
1.3
Jakeman David

VP of Finance and Accounting

Officer
3,610 -2.6%
0.99
US$3,584 		3,610 -2.6% 0.99 US$3,584
2023-09-26 2023-09-25 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
20,000 +33.3%
0.98
US$19,636 		20,000 +33.3% 0.98 US$19,636
2023-05-19 2023-05-18 PP Planned purchase
3.1
Andriole Michael T.

Chief Business Officer and CFO

Officer
51,700 +16.9%
1.14
US$59,150 		51,700 +16.9% 1.14 US$59,150
2023-05-16 2023-05-12 B Purchase
2.8
Sherman Michael A.

Chief Executive Officer

Executive Director
75,015 +625.9%
1.12
US$84,122 		75,015 +625.9% 1.12 US$84,122
2023-05-16 2023-05-12 B Purchase
2.8
Sherman Michael A.

Chief Executive Officer

Executive Director
11,985 +inf%
1.13
US$13,530 		11,985 +inf% 1.13 US$13,530
2023-05-11 2023-05-10 B Purchase
2.5
DEMSKI MARTHA J
Non-Executive Director
18,000 +33.3%
1.11
US$19,980 		18,000 +33.3% 1.11 US$19,980
2023-05-10 2023-05-08 B Purchase
2.8
Meyer Robert J.
Non-Executive Director
8,750 +33.1%
1.14
US$9,975 		8,750 +33.1% 1.14 US$9,975
2023-03-29 2023-03-28 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
20,000 +50.0%
1.21
US$24,152 		20,000 +50.0% 1.21 US$24,152
2023-01-26 2023-01-26 PlS Planned sale
1.3
Jakeman David

Principal Accounting Officer

Officer
3,230 -2.3%
1.76
US$5,686 		3,230 -2.3% 1.76 US$5,686
2022-10-03 2022-09-29 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
20,000 +100.0%
1.86
US$37,176 		20,000 +100.0% 1.86 US$37,176
2022-05-20 2022-05-19 B Purchase
2.8
Meyer Robert J.
Non-Executive Director
1,419 +5.7%
2.05
US$2,909 		1,419 +5.7% 2.05 US$2,909
2022-05-20 2022-05-19 B Purchase
2.8
Meyer Robert J.
Non-Executive Director
9,981 +66.5%
2.06
US$20,561 		9,981 +66.5% 2.06 US$20,561
2022-05-20 2022-05-19 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
20,000 +inf%
2.04
US$40,738 		20,000 +inf% 2.04 US$40,738
2022-05-18 2022-05-17 PP Planned purchase
3.1
Andriole Michael T.

Chief Business Officer and CFO

Officer
15,000 +7.6%
1.71
US$25,635 		15,000 +7.6% 1.71 US$25,635
2022-05-17 2022-05-17 B Purchase
2.5
DEMSKI MARTHA J
Non-Executive Director
10,000 +22.7%
1.61
US$16,100 		10,000 +22.7% 1.61 US$16,100
2022-02-04 2022-02-04 PlS Planned sale
1.3
Jakeman David

Principal Accounting Officer

Officer
3,300 -2.7%
5.56
US$18,355 		3,300 -2.7% 5.56 US$18,355
2021-06-29 2021-06-28 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
6,950 +3.5%
7.83
US$54,418 		6,950 +3.5% 7.83 US$54,418
2021-06-29 2021-06-25 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
3,050 +1.5%
7.78
US$23,729 		3,050 +1.5% 7.78 US$23,729
2021-04-07 2021-04-05 PlS Planned sale
1.3
Jakeman David

Principal Accounting Officer

Officer
1,284 -1.2%
9.68
US$12,427 		1,284 -1.2% 9.68 US$12,427
2021-03-01 2021-03-01 B Purchase
2.8
Meyer Robert J.
Non-Executive Director
1,500 +11.1%
9.80
US$14,700 		1,500 +11.1% 9.80 US$14,700
2021-01-29 2021-01-28 PlS Planned sale
1.3
Jakeman David

Principal Accounting Officer

Officer
3,211 -3.2%
8.61
US$27,650 		3,211 -3.2% 8.61 US$27,650
2020-10-02 2020-10-02 PlS Planned sale
1.3
Jakeman David

Principal Accounting Officer

Officer
4,270 -4.8%
2.48
US$10,590 		4,270 -4.8% 2.48 US$10,590
2020-08-19 2020-08-19 B Purchase
2.8
Meyer Robert J.
Non-Executive Director
3,500 +35.0%
2.92
US$10,220 		3,500 +35.0% 2.92 US$10,220
2020-08-11 2020-08-10 PlS Planned sale
2.5
DEMSKI MARTHA J
Non-Executive Director
1,584 -100.0%
3.25
US$5,148 		1,584 -100.0% 3.25 US$5,148
2020-08-10 2020-08-07 PlS Planned sale
2.5
DEMSKI MARTHA J
Non-Executive Director
2,500 -100.0%
3.25
US$8,125 		2,500 -100.0% 3.25 US$8,125
2020-08-10 2020-08-06 PlS Planned sale
2.5
DEMSKI MARTHA J
Non-Executive Director
2,500 -100.0%
3.29
US$8,224 		2,500 -100.0% 3.29 US$8,224
2020-08-06 2020-08-05 PlS Planned sale
2.5
DEMSKI MARTHA J
Non-Executive Director
2,500 -100.0%
3.27
US$8,187 		2,500 -100.0% 3.27 US$8,187
2020-08-06 2020-08-04 PlS Planned sale
2.5
DEMSKI MARTHA J
Non-Executive Director
5,000 -100.0%
3.25
US$16,250 		5,000 -100.0% 3.25 US$16,250
2020-03-17 2020-03-16 PP Planned purchase
3.1
Andriole Michael T.

Chief Business Officer

Officer
33,300 +28.6%
1.43
US$47,522 		33,300 +28.6% 1.43 US$47,522
2020-03-16 2020-03-12 B Purchase
2.8
Sherman Michael A.

Chief Executive Officer

Executive Director
72,995 +243.3%
1.45
US$105,653 		72,995 +243.3% 1.45 US$105,653
2020-03-16 2020-03-12 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
50,000 +33.9%
1.40
US$69,900 		50,000 +33.9% 1.40 US$69,900
2020-02-11 2020-02-10 S Sale
3.0
Nichols Garrett

Chief Medical Officer

Officer
8,805 -3.3%
1.68
US$14,830 		8,805 -3.3% 1.68 US$14,830
2020-02-11 2020-02-07 S Sale
3.0
Nichols Garrett

Chief Medical Officer

Officer
2,550 -0.9%
1.70
US$4,335 		2,550 -0.9% 1.70 US$4,335
2020-02-11 2020-02-07 S Sale
1.3
Jakeman David

Principal Accounting Officer

Officer
2,290 -2.5%
1.70
US$3,893 		2,290 -2.5% 1.70 US$3,893
2020-01-08 2020-01-07 S Sale
3.0
Nichols Garrett

Chief Medical Officer

Officer
30,680 -10.2%
2.15
US$66,045 		30,680 -10.2% 2.15 US$66,045
2019-11-13 2019-11-13 B Purchase MIDDLETON FRED A Non-Executive Director
30,000 +25.5%
1.82
US$54,567 		30,000 +25.5% 1.82 US$54,567
2019-11-13 2019-11-11 B Purchase MIDDLETON FRED A Non-Executive Director
20,000 +20.5%
1.66
US$33,190 		20,000 +20.5% 1.66 US$33,190
2019-11-07 2019-11-06 B Purchase
3.1
Andriole Michael T.

Chief Business Officer
100,000 +inf%
1.56
US$156,000 		100,000 +inf% 1.56 US$156,000
2019-11-06 2019-11-06 B Purchase Meyer Robert J. Non-Executive Director
10,000 +inf%
1.58
US$15,797 		10,000 +inf% 1.58 US$15,797
2019-05-29 2019-05-28 B Purchase
2.5
DEMSKI MARTHA J
Non-Executive Director
18,000 +94.7%
3.60
US$64,800 		18,000 +94.7% 3.60 US$64,800
2019-05-20 2019-05-20 B Purchase
2.8
Sherman Michael A.

Chief Executive Officer

Executive Director
30,000 +inf%
3.48
US$104,316 		30,000 +inf% 3.48 US$104,316
2019-05-13 2019-05-10 B Purchase
2.6
MIDDLETON FRED A
Non-Executive Director
30,000 +44.4%
2.92
US$87,678 		30,000 +44.4% 2.92 US$87,678
2018-06-14 2018-06-12 B Purchase Berrey M Michelle

President and CEO

Executive Director
10,000 +11.2%
4.50
US$45,015 		10,000 +11.2% 4.50 US$45,015
2018-05-21 2018-05-18 S Sale MARIO ERNEST Non-Executive Director
15,000 -12.2%
4.81
US$72,142 		15,000 -12.2% 4.81 US$72,142
2018-05-21 2018-05-17 S Sale MARIO ERNEST Non-Executive Director
30,000 -19.6%
4.80
US$143,931 		30,000 -19.6% 4.80 US$143,931
2018-05-17 2018-05-16 S Sale MARIO ERNEST Non-Executive Director
30,000 -16.4%
4.79
US$143,808 		30,000 -16.4% 4.79 US$143,808
2018-05-16 2018-05-15 S Sale MARIO ERNEST Non-Executive Director
30,000 -14.1%
4.69
US$140,808 		30,000 -14.1% 4.69 US$140,808
2018-05-15 2018-05-14 S Sale MARIO ERNEST Non-Executive Director
22,553 -9.6%
4.67
US$105,232 		22,553 -9.6% 4.67 US$105,232
Explore more

More insider trading research around Chimerix Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America